Agile Therapeutics (AGRX) Revenue & Revenue Breakdown
Agile Therapeutics Revenue Highlights
Latest Revenue (Y)
$19.59M
Latest Revenue (Q)
$5.58M
Agile Therapeutics Revenue by Period
Agile Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $19.59M | 80.02% |
2022-12-31 | $10.88M | 165.40% |
2021-12-31 | $4.10M | 447.53% |
2020-12-31 | $749.00K | 100.00% |
2019-12-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2017-12-31 | - | 100.00% |
2016-12-31 | - | 100.00% |
2015-12-31 | - | 100.00% |
2014-12-31 | - | 100.00% |
2013-12-31 | - | 100.00% |
2012-12-31 | - | - |
Agile Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | $5.58M | -2.45% |
2024-03-31 | $5.72M | 58.16% |
2023-12-31 | $3.61M | -45.75% |
2023-09-30 | $6.66M | 21.06% |
2023-06-30 | $5.50M | 44.32% |
2023-03-31 | $3.81M | -4.58% |
2022-12-31 | $4.00M | 33.11% |
2022-09-30 | $3.00M | 41.20% |
2022-06-30 | $2.13M | 20.73% |
2022-03-31 | $1.76M | 16.31% |
2021-12-31 | $1.51M | 17.64% |
2021-09-30 | $1.29M | 8.61% |
2021-06-30 | $1.19M | 921.55% |
2021-03-31 | $116.00K | -84.51% |
2020-12-31 | $749.00K | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2019-09-30 | - | 100.00% |
2019-06-30 | - | 100.00% |
2019-03-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2018-09-30 | - | 100.00% |
2018-06-30 | - | 100.00% |
2018-03-31 | - | 100.00% |
2017-12-31 | - | 100.00% |
2017-09-30 | - | 100.00% |
2017-06-30 | - | 100.00% |
2017-03-31 | - | 100.00% |
2016-12-31 | - | 100.00% |
2016-09-30 | - | 100.00% |
2016-06-30 | - | 100.00% |
2016-03-31 | - | 100.00% |
2015-12-31 | - | 100.00% |
2015-09-30 | - | 100.00% |
2015-06-30 | - | 100.00% |
2015-03-31 | - | 100.00% |
2014-12-31 | - | 100.00% |
2014-09-30 | - | 100.00% |
2014-06-30 | - | 100.00% |
2014-03-31 | - | 100.00% |
2013-12-31 | - | 100.00% |
2013-09-30 | - | 100.00% |
2013-06-30 | - | 100.00% |
2013-03-31 | - | - |
Agile Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
PTPI | Petros Pharmaceuticals | $5.82B | $1.39M |
AMRX | Amneal Pharmaceuticals | $2.39B | $701.78M |
ASRT | Assertio | $152.07M | $31.13M |
LFCR | Lifecore Biomedical | $128.26M | $35.70M |
AQST | Aquestive Therapeutics | $50.58M | $20.10M |
CPIX | Cumberland Pharmaceuticals | $39.55M | $9.85M |
TKNO | Alpha Teknova | $36.68M | $9.61M |
AGRX | Agile Therapeutics | $19.59M | $5.58M |
GHSI | Guardion Health Sciences | $12.25M | $36.35K |
EVOK | Evoke Pharma | $5.18M | $1.74M |
CYTH | Cyclo Therapeutics | $1.08M | $123.10K |
ACRX | Talphera | $651.00K | $117.00K |
SHPH | Shuttle Pharmaceuticals | - | - |
PRFX | PainReform | - | - |
AGRX Revenue FAQ
What is Agile Therapeutics’s yearly revenue?
Agile Therapeutics's yearly revenue for 2023 was $19.59M, representing an increase of 80.02% compared to 2022. The company's yearly revenue for 2022 was $10.88M, representing an increase of 165.40% compared to 2021. AGRX's yearly revenue for 2021 was $4.1M, representing an increase of 447.53% compared to 2020.
What is Agile Therapeutics’s quarterly revenue?
Agile Therapeutics's quarterly revenue for Q2 2024 was $5.58M, a -2.45% decrease from the previous quarter (Q1 2024), and a 1.33% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $5.72M, a 58.16% increase from the previous quarter (Q4 2023), and a 49.91% increase year-over-year (Q1 2023). AGRX's quarterly revenue for Q4 2023 was $3.61M, a -45.75% decrease from the previous quarter (Q3 2023), and a -9.56% decrease year-over-year (Q4 2022).
What is Agile Therapeutics’s revenue growth rate?
Agile Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 377.76%, and for the last 5 years (2019-2023) was 0%.